Western Eastern Europe – Another Region on a Global Map of International Clinical Trials
The region of Central and Eastern Europe (CEE) entered the international clinical trials (CT) arena about 20 years ago, and now it plays an important role in the clinical trial market, providing up to 9-10% of global enrolment. The CEE region includes more than 20 post-communist countries, and has a population of more than 340 million people. 11 of these countries have already joined the European Union (EU). Pharmaceutical research and development far outpace the market. This is important since pharmaceutical companies continuously channel 10-20% of revenues to research and development. While expenditure grows, the initial costs remain practically unchanged, which compels pharmaceutical companies to look for practical solutions to this situation. Tomas Novak, PharmD (Czech Republic), Maxim Belotserkovsky, MD (Germany), Veronika Fekete, MD (Hungary) and Katarzyna Moscicka PharmD (Poland) discuss why the CEE region is one of the optimal options due to rapid enrolment, high quality of data, motivation and loyalty of investigators, low dropout rate, reasonable costs, and educated clinical research professionals.
http://jforcs.com/jcs/wp-content/uploads/2013/04/Western-Eastern-Europe-Another-Region-on-a-Global-Map-of-International-Clinical-Trials.pdf